Bayer Extends CEO Bill Anderson’s Contract; Sarepta C-Suite Turmoil

Bayer has extended CEO Bill Anderson's contract by three years, now set to expire March 31, 2029, as he leads a major company transformation addressing legal liabilities, debt, and operational restructuring1234.

Since Anderson took over in June 2023, Bayer has reduced management positions by about half, eliminated about 11,000 jobs, and is targeting €2 billion ($2.17 billion) in savings by 20261.

Bayer's strategic priorities include strengthening its pharma pipeline, improving crop science profitability, rolling out its "Dynamic Shared Ownership" model, reducing debt, and resolving US legal risks related to Roundup herbicide litigation13.

Anderson's contract extension reflects unanimous support from the supervisory board, as he pursues a turnaround and cultural shift to make Bayer "the leanest, fastest, most innovative life science company"23.

No recent information about C-suite changes at Sarepta Therapeutics appears in the provided results; additional sources may be required for the latest developments at Sarepta.

Sources:

1. https://www.feedandgrain.com/business-markets/company-news/news/15750927/bayer-extends-ceo-andersons-contract-through-2029-amid-company-transformation

2. https://www.thepharmaletter.com/pharmaceutical/bayer-backs-ceo-bill-anderson-with-contract-extension-through-2029

3. https://www.efanews.eu/item/52266-bayer-bill-anderson-s-tenure-extended.html

4. https://seekingalpha.com/news/4467987-bayer-ag-extends-contract-of-ceo-bill-anderson